NCT03196271 is a NA clinical trial of Ketocal 2.5:1 in Intractable Epilepsy, sponsored by Nutricia UK Ltd.

Who is sponsoring NCT03196271?

NCT03196271 is sponsored by Nutricia UK Ltd.

What drugs are being tested in NCT03196271?

Interventions in NCT03196271: Ketocal 2.5:1.

What condition does NCT03196271 study?

NCT03196271 studies Intractable Epilepsy.

Is NCT03196271 still recruiting?

NCT03196271 is currently completed. Last updated 8 July 2019.

Last reviewed 2019-07-08 · How we verify

NCT03196271

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketogenic Diet Drink Study

Completed NA Last updated 8 July 2019

What this trial tests

NA trial testing Ketocal 2.5:1 in Intractable Epilepsy in 26 participants. Completed in 10 December 2018.

Timeline

4 January 2017

Primary endpoint
10 December 2018

10 December 2018

Quick facts

Lead sponsor	Nutricia UK Ltd
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	26
Start date	4 January 2017
Primary completion	10 December 2018
Estimated completion	10 December 2018
Sites	9 locations across United Kingdom

Drugs / interventions tested

Ketocal 2.5:1

Conditions studied

Intractable Epilepsy — all drugs for Intractable Epilepsy →

Sponsor

Nutricia UK Ltd

Who can join

8 and older, any sex, with Intractable Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An evaluation of the tolerance, compliance, acceptability and safety of a nutritionally complete liquid feed for use as part of the ketogenic diet (KD) in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tolerance, adherence, and acceptability of a ketogenic 2.5:1 ratio, nutritionally complete, medium chain triglyceride-containing liquid feed in children and adults with drug-resistant epilepsy following a ketogenic diet.
Griffen C, Schoeler NE, Browne R, Cameron T, et al · · 2024 · cited 10× · PMID 38411329 · DOI 10.1002/epi4.12910

Verify or expand the search:

Other recruiting trials for Intractable Epilepsy

Currently open trials in the same condition.

NCT05600738 — Network Effects of Therapeutic Deep Brain Stimulation · NA · recruiting

Other Nutricia UK Ltd trials

Trials by the same sponsor.

NCT06941532 — GMP Powdered Substitutes in PKU and TYR · NA · recruiting
NCT04272736 — PKU Low Calorie Drink Study · NA · withdrawn
NCT05822557 — Bolus Pouch Feed Study · NA · completed
NCT05411848 — 2kcal Tube Feed Study · NA · completed
NCT05269992 — Childrens Real Food Tolerance Study · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03196271 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nutricia UK Ltd
Last refreshed: 8 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03196271.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing